Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss

NCT ID: NCT00471172

Last Updated: 2008-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine. The methods differed in the type and frequency of counseling utilized to deliver dietary, physical activity and behavioral recommendations for weight loss.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)

Intervention Type BEHAVIORAL

Face-to-face counseling by a dietitian (monthly)

Intervention Type BEHAVIORAL

Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)

Intervention Type BEHAVIORAL

Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)

Intervention Type BEHAVIORAL

Self help

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1- Body mass index -calculated as weight in kilograms divided by the square of height in meters- ≥30 and \<40 kg/m2.
* 2- Eligibility to be prescribed sibutramine, following the eligibility requirements listed in the US Package Insert
* 3- Willingness and ability to comply with study related procedures
* 4- Access to Internet and email

Exclusion Criteria

* Uncontrolled blood pressure (defined as ≥140/90 mmHg), diabetes, coronary heart disease, chronic congestive heart failure, stroke, significant metabolic, hepatic or renal disease, current malignancy, gastric bypass surgery or had a weight loss ≥10%, participated in a structured weight loss program, or had taken weight loss agents during the past 6 months. Women were excluded if pregnant or breastfeeding; women of childbearing potential had to use adequate contraception.
Minimum Eligible Age

25 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Los Angeles, California, United States

Site Status

Pfizer Investigational Site

Clearwater, Florida, United States

Site Status

Pfizer Investigational Site

Kissimmee, Florida, United States

Site Status

Pfizer Investigational Site

Pembroke Pines, Florida, United States

Site Status

Pfizer Investigational Site

Lexington, Kentucky, United States

Site Status

Pfizer Investigational Site

Louisville, Kentucky, United States

Site Status

Pfizer Investigational Site

Milford, Massachusetts, United States

Site Status

Pfizer Investigational Site

Charlotte, North Carolina, United States

Site Status

Pfizer Investigational Site

Harleysville, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Warwick, Rhode Island, United States

Site Status

Pfizer Investigational Site

Nashville, Tennessee, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A9001187

Identifier Type: -

Identifier Source: org_study_id